Non-alcoholic fatty liver disease is predicted to become the leading indicator for liver transplant necessity within the ...

Gary Miller remembers being told by a [former] doctor that his fatty liver disease was a “benign condition.”“This doctor ...

Nonalcoholic fatty liver disease (NAFLD) was linked to elevated liver enzymes in type 2 diabetes mellitus (T2DM) in a recent ...

Metabolic dysfunction–associated steatohepatitis (MASH) is the new term for non-alcoholic steatohepatitis (NASH). There are several reasons for the name change.

The Global Liver Institute urges worldwide integration of liver health into diabetes and obesity care as steatotic liver ...

The global emergence of obesity as an epidemic has made fatty liver disease a public health problem in the Western world. The increased incidence of obesity has been paralleled by an increase in ...

Dapagliflozin effectively treats fatty liver disease (MASH), reducing liver fat and scarring. Black patient involvement in ...

Gastroenterologist Dr. Wendi explains how fatty liver disease progresses and why early action is crucial to prevent serious liver damage.

Nearly a quarter saw their fatty liver disease resolve using the drug Originally published on healthday.com, part of the BLOX ...

The cutting-edge weight-loss drug Ozempic/Wegovy can stop and even reverse fatty liver disease, a new clinical trial has found. Nearly twice as many people taking semaglutide stopped their fatty ...

Fat in the liver—where it doesn’t belong–can cause nonalcoholic fatty liver disease (NAFLD), which is estimated to affect 36 percent of US adults. According to a recent blog by Dr. Michael Greger ...